Other OTC - Delayed Quote • USD
Mydecine Innovations Group Inc. (MYCOF)
As of 9:30 AM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Joshua Bartch | Co-Founder, CEO, President & Chairman of the Board | 324.44k | -- | 1988 |
| Mr. Robert Roscow M.A. | Co-Founder, Chief Scientific Officer & Director | 332.31k | -- | -- |
| Mr. Damon Michaels | Co-Founder & COO | 332.31k | -- | -- |
| Mr. John Charles Ross CA, CPA, M.B.A. | CFO & Corporate Secretary | 6.71k | -- | 1958 |
| Mr. Sanford M. Stein | Chief Compliance Officer & General Counsel | 231.63k | -- | -- |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer | 197.94k | -- | -- |
| Morgan Kervitsky | Director of Marketing | -- | -- | -- |
| Mr. Michel Rudolphie | President of the European Operations | -- | -- | -- |
| Mr. William Cook | Interim CEO & Technical Director of Mindleap Health Inc. | -- | -- | -- |
Mydecine Innovations Group Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 3
Description
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Corporate Governance
Mydecine Innovations Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Jun 15, 2022D: Additional FormsSee Full Filing
- Apr 01, 2019Dividend Date
Upcoming Events
May 13, 2024 - May 17, 2024
Mydecine Innovations Group Inc. Earnings Call
Related Tickers
LMLLF Pharmadrug Inc.
0.0252
+18.87%
FLHLF Filament Health Corp.
0.0377
0.00%
RVVTF Revive Therapeutics Ltd.
0.0215
+6.97%
TRUFF Red Light Holland Corp.
0.0443
+4.85%
NXGB NxGen Brands Inc.
0.0035
-47.29%
SBBCF Simply Better Brands Corp.
0.2668
+4.18%
NXEN Nexien BioPharma, Inc.
0.0209
-28.02%
MGWFF Maple Leaf Green World Inc.
0.0346
0.00%
DBCCF Decibel Cannabis Company Inc.
0.0966
-4.40%
BBBT Black Bird Biotech, Inc.
0.0002
0.00%